Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Preferential response of cancer cells to zebularine.

Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G, Marquez VE, Greer S, Orntoft TF, Thykjaer T, Jones PA.

Cancer Cell. 2004 Aug;6(2):151-8.

2.

Zebularine: a candidate for epigenetic cancer therapy.

Bradbury J.

Drug Discov Today. 2004 Nov 1;9(21):906-7.

PMID:
15501719
3.

DNA methyltransferase inhibitor zebularine induces human cholangiocarcinoma cell death through alteration of DNA methylation status.

Nakamura K, Nakabayashi K, Htet Aung K, Aizawa K, Hori N, Yamauchi J, Hata K, Tanoue A.

PLoS One. 2015 Mar 23;10(3):e0120545. doi: 10.1371/journal.pone.0120545. eCollection 2015.

4.

Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells.

Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, Marquez VE, Jones PA.

Mol Cell Biol. 2004 Feb;24(3):1270-8.

5.

Inhibition of DNA methylation and reactivation of silenced genes by zebularine.

Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA, Selker EU.

J Natl Cancer Inst. 2003 Mar 5;95(5):399-409.

PMID:
12618505
6.

Zebularine enhances apoptosis of human osteosarcoma cells by suppressing methylation of ARHI.

Ye K, Wang S, Wang J, Han H, Ma B, Yang Y.

Cancer Sci. 2016 Dec;107(12):1851-1857. doi: 10.1111/cas.13088. Epub 2016 Dec 19.

7.

Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A.

Chen M, Voeller D, Marquez VE, Kaye FJ, Steeg PS, Giaccone G, Zajac-Kaye M.

Int J Oncol. 2010 Oct;37(4):963-71.

PMID:
20811718
8.

Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy.

Marquez VE, Kelley JA, Agbaria R, Ben-Kasus T, Cheng JC, Yoo CB, Jones PA.

Ann N Y Acad Sci. 2005 Nov;1058:246-54. Review.

PMID:
16394141
9.

DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer.

Chen M, Shabashvili D, Nawab A, Yang SX, Dyer LM, Brown KD, Hollingshead M, Hunter KW, Kaye FJ, Hochwald SN, Marquez VE, Steeg P, Zajac-Kaye M.

Mol Cancer Ther. 2012 Feb;11(2):370-82. doi: 10.1158/1535-7163.MCT-11-0458. Epub 2011 Dec 27.

10.

Zebularine: a new drug for epigenetic therapy.

Yoo CB, Cheng JC, Jones PA.

Biochem Soc Trans. 2004 Dec;32(Pt 6):910-2. Review.

PMID:
15506921
11.

Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer.

Balch C, Yan P, Craft T, Young S, Skalnik DG, Huang TH, Nephew KP.

Mol Cancer Ther. 2005 Oct;4(10):1505-14.

12.

Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine.

Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, Camphausen K, Tofilon PJ.

Clin Cancer Res. 2005 Jun 15;11(12):4571-9.

13.

The DNA methyltransferase inhibitor zebularine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo.

Tan W, Zhou W, Yu HG, Luo HS, Shen L.

Biochem Biophys Res Commun. 2013 Jan 4;430(1):250-5. doi: 10.1016/j.bbrc.2012.10.143. Epub 2012 Nov 17.

PMID:
23167995
14.

DNA methylation and cancer.

Kulis M, Esteller M.

Adv Genet. 2010;70:27-56. doi: 10.1016/B978-0-12-380866-0.60002-2. Review.

PMID:
20920744
15.

DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells.

Robert MF, Morin S, Beaulieu N, Gauthier F, Chute IC, Barsalou A, MacLeod AR.

Nat Genet. 2003 Jan;33(1):61-5. Epub 2002 Dec 23.

PMID:
12496760
16.

Epigenetic tête-à-tête: the bilateral relationship between chromatin modifications and DNA methylation.

D'Alessio AC, Szyf M.

Biochem Cell Biol. 2006 Aug;84(4):463-76. Review.

PMID:
16936820
17.

DNMT1 and DNMT3b cooperate to silence genes in human cancer cells.

Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B.

Nature. 2002 Apr 4;416(6880):552-6.

PMID:
11932749
18.

DNA methylation and cancer therapy.

Szyf M.

Drug Resist Updat. 2003 Dec;6(6):341-53. Review.

PMID:
14744498
19.

Hypomethylation of cytosine 5-methyltransferase in human neoplasms.

Butler TL, Kay PH, Jacobsen PF.

Anticancer Res. 2000 May-Jun;20(3A):1435-8.

PMID:
10928053
20.

Supplemental Content

Support Center